Pay in 4 interest-free payments of $6.47 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
In many cases, the side effects of GLP-1 treatment are temporary
Here we show that oral administration of the non-calorie sweetener, rare sugar d-allulose (d-psicose), induces GLP-1 release, activates vagal afferent signaling, reduces food intake and promotes glucose tolerance in healthy and obese-diabetic animal models
Primary antibodies (Table S1) diluted in TN buffer (0.1 M TrisHCl, 0.15 M NaCl, pH 7.5) were reacted overnight at 4 C
2025, doi: 10.1001/jama.2025.24288
Companies that can deliver nutrient-dense, satisfying beverage experiences in appropriately sized portions stand to capture significant market opportunities as the GLP-1 user base expands beyond current demographics into mainstream consumer segments
Study: Glucagon-like peptide 1 receptor agonist discontinuation and risks of major adverse cardiovascular events in adults with type 2 diabetes: target trial emulation
US$ 20.26
US$ 23.32
US$ 25.53
